BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23225412)

  • 1. Synergistic anticancer activity of Thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells.
    González-Sánchez I; Lira-Rocha A; Navarrete A; Loza-Mejía MA; Coronel-Cruz C; Mendoza-Rodríguez CA; Cerbón MA
    Anticancer Res; 2012 Dec; 32(12):5159-65. PubMed ID: 23225412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antineoplastic activity of the thiazolo[5,4-b]quinoline derivative D3CLP in K-562 cells is mediated through effector caspases activation.
    González-Sánchez I; Solano JD; Loza-Mejía MA; Olvera-Vázquez S; Rodríguez-Sotres R; Morán J; Lira-Rocha A; Cerbón MA
    Eur J Med Chem; 2011 Jun; 46(6):2102-8. PubMed ID: 21420205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic Profiling Reveals the Induction of UPR in Addition to DNA Damage Response in HeLa Cells Treated With the Thiazolo[5,4-b]Quinoline Derivative D3ClP.
    Páez-Franco JC; González-Sánchez I; Gutiérrez-Nájera NA; Valencia-Turcotte LG; Lira-Rocha A; Cerbón MA; Rodríguez-Sotres R
    J Cell Biochem; 2017 May; 118(5):1164-1173. PubMed ID: 27684057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines.
    García-López P; Rodríguez-Dorantes M; Pérez-Cárdenas E; Cerbón M; Mohar-Betancourt A
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):533-40. PubMed ID: 15138713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro combined effect of a new series of copper (II) complexes with cisplatin or epirubicin on human breast and cervical cancer cell lines.
    Geromichalos GD; Katsoulos GA; Hadjikostas CC; Kortsaris AH; Kyriakidis DA
    Drugs Exp Clin Res; 1998; 24(2):93-104. PubMed ID: 9675550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
    Yerushalmi R; Nordenberg J; Beery E; Uziel O; Lahav M; Luria D; Fenig E
    Exp Oncol; 2007 Jun; 29(2):126-31. PubMed ID: 17704745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines].
    Nagasawa M; Ishii S; Kariya Y; Itoh O; Yamamoto H; Kawaharajo K; Takeuchi T
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):633-8. PubMed ID: 2108612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the Medicago scutellata trypsin inhibitor (MsTI) on cisplatin-induced cytotoxicity in human breast and cervical cancer cells.
    Lanza A; Tava A; Catalano M; Ragona L; Singuaroli I; Robustelli della Cuna FS; Robustelli della Cuna G
    Anticancer Res; 2004; 24(1):227-33. PubMed ID: 15015601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibitory and adjuvant therapeutic potential of aqueous extract of Triticum aestivum on MCF-7 and HeLa cells.
    Hussain A; Gheewala TM; Vas AJ; Shah K; Goala P; Khan S; Hinduja S; Sharma C
    Exp Oncol; 2014 Mar; 36(1):9-16. PubMed ID: 24691278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
    Kendrick JE; Straughn JM; Oliver PG; Wang W; Nan L; Grizzle WE; Stockard CR; Alvarez RD; Buchsbaum DJ
    Gynecol Oncol; 2008 Mar; 108(3):591-7. PubMed ID: 18177927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myricetin and methyl eugenol combination enhances the anticancer activity, cell cycle arrest and apoptosis induction of cis-platin against HeLa cervical cancer cell lines.
    Yi JL; Shi S; Shen YL; Wang L; Chen HY; Zhu J; Ding Y
    Int J Clin Exp Pathol; 2015; 8(2):1116-27. PubMed ID: 25972998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy.
    Wesierska-Gadek J; Kramer MP; Schmid G
    J Cell Biochem; 2008 May; 104(1):189-201. PubMed ID: 18022825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells.
    Wang Y; Yang Z; Zhao X
    Toxicol Mech Methods; 2010 Jun; 20(5):234-41. PubMed ID: 20374036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
    Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
    Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
    Wigington DP; Urben CM; Strugnell SA; Knutson JC
    Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK; Agarwal C; Chan DC; Agarwal R
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.